Review article: The pharmacological inhibition of gastric acid secretion - Tolerance and rebound

Alimentary Pharmacology and Therapeutics

Volumn 11, Issue 6, 1997, Pages 1013-1018

  Sandvik, A K ^a,b   Brenna, E ^a   Waldum, H L ^b  

^a Department of Physiology and Biomédical Engineering ^*  (Norway)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; PROTON PUMP INHIBITOR;

ARTICLE; DRUG TOLERANCE; ENTEROCHROMAFFIN CELL; HISTAMINE RELEASE; HUMAN; PRIORITY JOURNAL; REBOUND; STOMACH ACID SECRETION; STOMACH PARIETAL CELL; THEORY;

EID: 0030809911     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1997.00257.x     Document Type: Article

References (51)

1. Merki HS, Wilder-Smith CH. Do continuous infusions of omeprazole and ranitidine retain their effect with prolonged dosing? Gastroenterology 1994; 106: 60-4.
2. Fullarton GM, McLauchlan G, MacDonald A, Crean GP, McColl KEL. Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist. Gut 1989; 30: 449-54.
3. Waldum HL, Arncstad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity in patients with reflux oesophagitis after a three months period with a proton pump inhibitor in a conventional dose. Gut 1996; 39: 649-53.
4. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995; 9(Suppl. 1): 9-14.
5. 2-receptor-antagonist-resistant reflux oesophagitis. Scand J Gastroenterol 1990; 25: 1144-50.
6. Viljakka M. Luostarinen M.'Isolauri J. Incidence of antireflux surgery in Finland 1988-1993. Scand J Gastroenterol 1997: 32:415-18.
7. 2 receptors. Gastroenterology 1974; 66: 517-21.
8. Kahlson G, Rosengren E, Svahn D, Thunberg R. Mobilization and formation of histamine in the gastric mucosa as related to acid secretion. J Physiol 1964; 174: 400-16.
9. Code CF. Histamine and gastric secretion. In: Wolstenholme G, O'Connor CM, eds. Ciba Foundation Symposium on Histamine. London: Churchill, 1956: 189-219.
10. Sandvik AK, Waldum HL, Kleveland PM. Schulze Sognen B. Gastrin produces an immediate and dose-dependent histamine release preceding acid secretion in the totally isolated, vascularly perfused rat stomach. Scand J Gastroenterol 1987; 22: 803-8.
11. Håkanson R, Böttcher G, Ekblad E. et al. Histamine in endocrine cells in the stomach: a survey of several species using a panel of histamine antibodies. Histochemistry 1986; 86: 5-17.
12. Brenna E, Waldum HL. Studies of isolated parietal and enterochromaffin-like cells from the rat. Scand J Gastroenterol 1991: 26: 1295-306.
13. Prinz C, Kajimura M, Scott DR, Mercier F, Helander HF. Sachs G. Histamine secretion from rat enterochromaffin-like cells. Gastroenterology 1993; 105: 449-61.
14. Soll AH, Toomey M, Culp D, Shanahan F, Beaven M. Modulation of histamine release from canine fundic mucosal mast cells. Am J Physiol 1988; 254 (Gastrointest. Liver Physiol. 17): G40-8.
15. Mårvik R, Sandvik AK, Waldum HL. Gastrin stimulates histamine release in the pig stomach. Scand J Gastroenterol 1997: 32: 2-5.
16. Gerber JG. Payne NA. The role of gastric secretagogues in regulating gastric histamine release in vivo. Gastroenterology 1992: 102: 403-8.
17. Roche S, Gusdinar T, Bali J-P, Magous R. 'Gastrin' and 'CCK' receptors of histamine- and somatostatin-containing cells from rabbit fundic mucosa - I. Characterization by means of agonists. Biochem Pharmacol 1991; 42: 765-70.
18. Nwokolo CU, Smith JTL, Gavey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4(Suppl. 1): 29-15.
19. Hurlimann S. Abbühl B. Inauen W, Halter F. Comparison of acid inhibition by either oral high-dose ranitidine or omeprazole. Aliment Pharmacol Ther 1994; 8: 193-201.
20. Walsh JH, Richardson CT. Fordtran JS. pH dependence of acid secretion and gastrin release in normal and ulcer patients. J Clin Invest 1975; 55: 462-9.
21. Smith JTL, Gavey C, Nwokolo CU, Pounder RE. Tolerance during 8 days of high-dose H2-blockade: placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Ther 1990; 4(Suppl. 1): 47-63.
22. Rogers MJ, Holmfleld JHM, Primrose JN, Johnston D. The effects of 15 days of dosing with placebo, sufotidine 600 mg nocte or sufotidine 600 mg twice daily upon 24-hour intragastric acidity and 24-hour plasma gastrin. Aliment Pharmacol Ther 1990; 4(SuppI. 1): 65-74.
23. Nwokolo CU, Prewett EJ, Sawyerr AM, Hudson M, Lim S, Pounder RE. Tolerance during 5 months of dosing with ranitidine, 150 mg nightly: A placebo-controlled, double-blind study. Gastroenterology 1991; 101: 948-53.
24. Loiselle J, Wollin A. Mucosal histamine elimination and its effect on acid secretion in rabbit gastric mucosa. Gastroenterology 1993; 104: 1013-20.
25. Sandvik AK, Mårvik R, Evans D, Waldum HL, Dimaline R. Gastrin regulates histidine decarboxylase (HDC) activity and mRNA abundance in the rat. Am J Physiol 1994; 267: G254-8.
26. Solcia E. Capella C, Fiocca R, Rindi G. Rosai J. Gastric argyrophil carcinoids in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 1990; 14: 503-13.
27. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985: 88: 638-18.
28. Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
29. Takeuchi K. Speir GR, Johnson LR. Mucosal gastrin receptor. III. Regulation by gastrin. Am J Physiol 1980; 238 (
30. Gastrointest. Liver Physiol. 1): G135-40.
31. Metz DC. Pisegna JR. Fishbeyn VA, et al Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high. Gastroenterology 1992; 103: 1498-508.
32. Saeed ZA, Norton JA, Frank WO, et al. Parenteral antisecretory drug therapy in patients with Zollinger-Ellison syndrome. Gastroenterology 1989; 96: 1393-402.
33. Zimmerhackl B, Wünsch E, Classen M, Schusdziarra V. Schepp W. In man histamine and muscarinergic mechanisms are essential mediators of acid secretion in response to synthetic human gastrin (1-17). Regul Pept 1993; 46: 583-92.
34. Leth R, Olbe L, Haglund U. The pentagastrin-induced gastric acid response in humans. Scand J Gastroenterol 1988; 23: 224-8.
35. Johnson LR, Aures D, Häkanson R. Effect of gastrin on the in vivo incorporation of C14-leucine into protein of the digestive tract. Proc Soc Exp Biol Med 1969; 132: 996-8.
36. Neuburger P, Lewin M, Bonfils S. Parietal and chief cell population in four cases of the Zollinger-Ellison syndrome. Gastroenterology 1972; 63: 937-42.
37. Ragins H, Wincze F, Liu SM. The origin of gastric parietal cells in the mouse. Anal Rec 1968; 162: 99-110.
38. +-ATPase α-subunit induced by omeprazole. Am J Physiol 1993; 265 (Gastrointest. Liver Physiol. 28): G752-8.
39. +-ATPase and histidine decarboxylase during omeprazole treatment. Digestion 1994; 55: 97-102.
40. Prewett EJ. Hudson M, Nwokolo CU, Sawyerr AM, Pounder RE. Nocturnal intragastric acidity during and after a period of dosing with either ranitidine or omeprazole. Gastroenterology 1991; 100: 873-7.
41. Bell N. Röhss K, Cederberg C, Hunt R. Does tachyphyiaxis and/ or rebound acid secretion occur during/after treatment with omeprazole or ranitidine? Gastroenterology 1993; 104: 41(Abstract).
42. Sandvik AK, Waldum HL. Rat gastric histamine release: a sensitive gastrin bioassay. Life Sci 1990; 46: 453-9.
43. Sewing KF, Hagie L, Ippoliti AF, Isenberg JI, Samloff IM, Sturdevant RAL. Effect of one month treatment with cimetidine on gastric secretion and serum gastrin and pepsinogen levels. Gastroenterology 1978: 74: 376-9.
44. Nwokolo CU, Smith JTL, Sawyerr AM, Pounder RE. Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade. Gut 1991: 32: 1455-60.
45. Waldum HL, Lehy T, Brenna E. et al. Effect of the histamine-1 antagonist astemizole alone or with omeprazole on rat gastric mucosa. Scand J Gastroenterol 1991: 26: 23-35.
46. Sharma B, Axelson M, Pounder RE, et al. Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects. Aliment Pharmacol Ther 1987; 1: 67-76.
47. Syversen U, Mignon M, Bonfils S, Kristensen A, Waldum H. Chromogranin A and pancreastatin-like immunoreactivity in serum of gastrinoma patients. Acta Oncol 1993: 32: 161-5.
48. Bell NJV, Burget D, Howden CW, Wilkinson J, Hunt RH. Appropriate acid suppression for the management of gastroesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 59-67.
49. Lundell L. Prevention of relapse of reflux oesophagitis after endoscopie healing: the efficacy and safety of omeprazole compared with ranitidine. Digestion 1990: 47(Suppl. 1): 72-5.
50. Lind T, Cederberg C. Ekenved G, Haglund U, Olbe L. Effect of omeprazole - a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-6.
51. Sharma BK, Walt RP, Pounder RE, Gomes M de FA, Wood EC, Logan LH. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984; 25: 957-64.